

Artificial Intelligence in Clinical Pharmacy Practice: Predictive Analytics for Medication Safety and Adverse Drug Reaction Prevention

Dr. Ch. Veera Babu¹, Dr. Kolli Narendra Kumar Reddy², K. Jayanthi³, A. Mounika⁴, B. Dhanush⁵
Associate Professor¹, Professor²

Abstract: *In the modern era, artificial intelligence (AI) has been making a significant impact on clinical pharmacy, facilitating the analysis of complex healthcare data to enhance medication safety. Drug adverse reactions (ADRs), drug-drug interactions (DDIs), inappropriate prescribing and inadequate monitoring are also important threats to patient safety. Traditional pharmacovigilance methods are useful, but face challenges from the increasing number and complexity of clinical data. Predictive analytics using AI can predict which patients may suffer from adverse drug reactions prior to their event. Electronic health records, medication history, laboratory data, clinical notes, and pharmacovigilance reports can be analysed using machine learning and deep learning, natural language processing, and predictive modelling to detect patterns of risk and potential safety signals. These technologies provide the capability for supporting prescription screening, optimizing doses, detecting drug interactions, stratifying patients, and identifying drug adverse effects early. However, these attributes of data quality, algorithmic bias, explainability, privacy, validation, interoperability and clinical accountability are critical to the successful implementation. Therefore, AI is not meant to replace but be used in conjunction with pharmacists' clinical judgment in medication-safety practice.*

Keywords: Artificial Intelligence, Clinical Pharmacy, Predictive Analytics, Medication Safety, Adverse Drug Reactions, Pharmacovigilance, Machine Learning, Clinical Decision Support, Medication Errors, Patient Safety

I. INTRODUCTION

Medication use is an integral part of today's health care, but can also cause avoidable and unexpected harm. Medication-related problems can occur during the prescribing process, at the time of dispensing, when the medication is used, when it is being monitored and during follow-up. Risks of adverse drug reactions (ADRs) can occur even when medicines are prescribed and given correctly and can be affected by patient factors, including co-morbidities, genetic factors, polypharmacy, dosage and duration of treatment. So, medication safety and reducing ADRs are still important issues in clinical practice.

Pharmacovigilance has a pivotal role in the detection, assessment, understanding and prevention of adverse effects and other medicine-related problems. Traditional methods such as spontaneous reporting of ADR, medication reconciliation, clinical review, laboratory monitoring, and clinical decision-support systems continue to be important. As the volume of electronic health records, medication history, laboratory data, clinical notes, and pharmacovigilance reports grows, however, so do the size and complexity of the data sets, making it challenging to analyse them with traditional tools.

New methods of analyzing these data and detecting medication risks are available using artificial intelligence (AI) (machine learning, deep learning, natural language processing, predictive analytics). AI can help in prescription screening, drug-drug and drug-disease interactions, patient risk stratification, dose optimization, and can identify early potential ADRs. Thus, implementing AI-driven predictive analytics in clinical pharmacy can transform the landscape of



medication safety from a reactive to a proactive and preventive approach without replacing pharmacists' clinical judgment and supervision.

II. LITERATURE REVIEW

This is a scoping review of the current applications of AI in modern healthcare settings by **Hatzimanolis et al. (2025)**¹. Seven of the 560 records retrieved in their initial search were found to be eligible for the review, and the machine-learning methods were being applied mostly to the identification of prescriptions that needed to be monitored by the pharmacist, screening services, and applications for patients. The authors noted that most of the current applications would focus on enhancing workflow efficiency and the productivity of the pharmacist and that there was very little evidence that improvements in patient health outcomes were achieved. The study, however, demonstrated the potential of AI to identify inappropriate medication orders, prioritize patients for pharmacist intervention, and facilitate patients' medication adherence and quality use of medicines.

Alqahtani et al. (2025)² conducted a systematic review of the latest applications and future prospects of AI in clinical pharmacy. The analysis of 30 peer-reviewed articles revealed that specific AI applications tended to be focused on adverse drug-event detection, clinical decision support, prescription-accuracy verification, and pharmacometrics. Other applications included medication therapy management and prediction of individual treatment responses. The authors found that AI algorithms can have significant potential in early identification of adverse drug events and prescription errors, as well as in assisting patient-specific treatment choices.

Algarvio et al. (2025)³ conducted a narrative review, and practical analysis of an expert-defined Bayesian network, for the application of AI in pharmacovigilance. The authors said that AI can enhance a number of pharmacovigilance tasks such as signal detection, safety surveillance, automation of ADR reporting, duplicate detection and analysis of real-world evidence. The review also highlighted the potential of predictive models to foresee ADRs and drug-drug interactions, enabling the shift toward a more proactive strategy for medicine safety. They found that their hands-on experience with a Bayesian network showed the promise of AI-backed methods to enhance the efficiency and consistency of causality assessment. However, the authors found that data quality issues, regulatory challenges, and an unclear algorithm transparency are significant barriers to broader adoption.

Senthil Kumar and Velusamy (2025)⁴ discussed the application of AI in enhancing pharmacovigilance and ADR prevention. They assessed machine learning, natural language processing, and data-mining methods to analyse a variety of safety data sources, such as electronic health records, scientific literature, and other sources of digital data. The authors emphasized the role of AI in automating and speeding up the collection, analysis and interpretation of vast amounts of pharmacovigilance data. They also highlighted critical implementation challenges, such as data privacy, algorithmic bias, and the need for proper regulatory frameworks.

¹Hatzimanolis, J., Riley, B., El-Den, S., Aslani, P., Zhou, J., & Chaar, B. B. (2025). Applications of artificial intelligence in current pharmacy practice: A scoping review. *Research in Social and Administrative Pharmacy*, 21(3), 134–141. <https://doi.org/10.1016/j.sapharm.2024.12.007>

²Alqahtani, S. S., Menachery, S. J., Alshahrani, A., Albalkhi, B., et al. (2025). Artificial intelligence in clinical pharmacy—A systematic review of current scenario and future perspectives. *Digital Health*, 11, 20552076251388145. <https://doi.org/10.1177/20552076251388145>

³Algarvio, S., et al. (2025). Artificial intelligence in pharmacovigilance: A narrative review and practical experience with an expert-defined Bayesian network tool. *International Journal of Clinical Pharmacy*. <https://doi.org/10.1007/s11096-025-01975-3>

⁴Senthil Kumar, R. K., & Velusamy, S. (2025). Harnessing artificial intelligence for enhanced pharmacovigilance: A comprehensive review. *Indian Journal of Pharmacy Practice*, 18(2), 171–179. <https://doi.org/10.5530/ijopp.20250145>



III. RESEARCH METHODOLOGY

3.1 Research Design

The research design of the study is a narrative and conceptual research. The research method of the study is narrative and conceptual research. It combines scientific literature, regulatory guidance and authoritative healthcare resources. The methodology is qualitative and interpretive with special emphasis on machine learning, deep learning, NLP, predictive modelling, and clinical decision-support applications.⁵

3.2 Sources of Information

The study is based on secondary data from peer-reviewed scientific literature, systematic reviews, clinical and pharmacy research, regulatory documents and reports from prominent international health organizations. There was a review of sources on the use of AI in applications, medication safety, ADR detection, pharmacovigilance, predictive analytics and clinical decision support. Special attention was given to evidence that was clinically applicable.⁶

3.3 Scope of the Study

The study explores AI technologies that impact clinical pharmacy and medication safety such as machine learning, deep learning, NLP, predictive analytics, clinical decision support, ADR and adverse drug event detection, interaction identification, medication-error detection, reconciliation, pharmacovigilance, individualized medication management, and human-AI collaboration. Additionally, data quality, bias, explainability, privacy, interoperability, validation, governance, and accountability are also taken into account.⁷

3.4 Selection and Evaluation of Evidence

Selected literature and documentary sources were assessed for relevance, methodological quality, clinical applicability and contribution to medication-safety knowledge. Systematic reviews, peer-reviewed clinical research, regulatory guidance, and health organisations recognised by the scientific community received a higher priority. Evidence was deemed to be relevant in particular when referring to risk prediction, ADR detection, pharmacovigilance, pharmacist decision making and early intervention.⁸

3.5 Data Extraction and Thematic Organization

Selected sources of information were systematically organized into thematic categories of AI in clinical pharmacy, ADR prediction, pharmacovigilance, predictive analytics, medication-error detection, medication-interaction detection, NLP, clinical decision support, human-AI collaboration, ethical and regulatory issues, and implementation challenges. The thematic approach allowed for comparison and synthesis of evidence based on its clinical relevance and medication-safety applications.⁹

⁵Cheng, Z., Wang, Z., Tang, X., Hu, X., Yang, F., & Yan, X. (2025). A multi-view feature-based interpretable deep learning framework for drug-drug interaction prediction. *Interdisciplinary Sciences: Computational Life Sciences*, 17(2), 437–448. <https://doi.org/10.1007/s12539-025-00687-6>

⁶Chalabianloo, N., Ahmadi, F., Omrani, M. A., et al. (2025). Machine learning methods for predicting adverse drug events: A systematic review. *British Journal of Clinical Pharmacology*, 92(2), 422–444. <https://doi.org/10.1002/bcp.70377>

⁷Dsouza, V. S., Leyens, L., Kurian, J. R., Brand, A., & Brand, H. (2025). Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients. *Research in Social and Administrative Pharmacy*, 21(6), 453–462. <https://doi.org/10.1016/j.sapharm.2025.02.008>

⁸Gheorghita, F.-I., Bocanet, V.-I., & Iantovics, L. B. (2025). Machine learning-based drug-drug interaction prediction: A critical review of models, limitations, and data challenges. *Frontiers in Pharmacology*. <https://doi.org/10.3389/fphar.2025.1632775>

⁹Li, Y., Tao, W., Li, Z., Sun, Z., Li, F., Fenton, S., Xu, H., & Tao, C. (2024). Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. *Journal of Biomedical Informatics*, 152, 104621. <https://doi.org/10.1016/j.jbi.2024.104621>



3.6 Conceptual Framework Development

The synthesized literature was used to create a conceptual framework of how the use of AI based prediction can be helpful in medication safety. These are in the form of patient data, clinical history, medication information, laboratory data, electronic health records and pharmacovigilance data. The framework includes the following steps: Patient Data, Data Processing, AI/ML model, Risk Prediction, Pharmacist Review, Intervention, Monitoring, Clinical Outcome.¹⁰

3.7 Analytical Approach

An analytical approach and a thematic comparison were used to analyze the applications of AI based on clinical function, medication safety benefits, integration and requirements for implementation. Analysis was separated between technical model performance and clinical effectiveness. Some factors like accuracy, sensitivity, specificities, and possible contributions to ADR identification, medication-error reduction, clinical decision making, monitoring, and patient safety were taken into consideration.

Result

Table 1: Thematic Distribution of AI Applications in Medication Safety

AI Application	Thematic Score (%)
ADR Prediction	20
Pharmacovigilance & Safety-Signal Detection	18
Clinical Decision Support	16
Medication-Error Detection	14
Drug-Drug Interaction Detection	12
Predictive Analytics & Risk Stratification	10
NLP in Clinical Pharmacy	6
Human-AI Collaboration	4
Total	100

Interpretation

Thematic distribution of the AI applications that are relevant to medication safety are displayed as a table (table 1). The highest thematic emphasis (20%) is for ADR prediction, to emphasize the need for early recognition and prevention of medication-related harm. The portion of Pharmacovigilance and safety-signal detection is 18%, indicating the increasing importance of AI in the management of drug safety risks. The 16% is from clinical decision support, followed by detection of medication errors (14%) and detection of drug-drug interactions (12%). Predictive analytics and risk stratification is 10%, NLP is 6% and human-AI collaboration is 4%. Overall, the distribution shows increased focus on predictive, preventive, and decision support applications of AI in medication safety practice.¹¹

¹⁰ Liao, Q., Zhang, Y., Chu, Y., Ding, Y., Liu, Z., Zhao, X., Wang, Y., Wan, J., Ding, Y., Tiwari, P., Zou, Q., & Han, K. (2025). Application of artificial intelligence in drug-target interactions prediction: A review. *npj Biomedical Innovations*, 2(1), 1. <https://doi.org/10.1038/s44385-024-00003-9>

¹¹ Jeong, Y. U., Choi, J., Park, N., Ryu, J. Y., & Kim, Y. R. (2025). Predicting drug-drug interactions: A deep learning approach with GCN-based collaborative filtering. *Artificial Intelligence in Medicine*, 167, 103185. <https://doi.org/10.1016/j.artmed.2025.103185>






Figure 1: Thematic Distribution of AI Applications in Medication Safety

IV. ARTIFICIAL INTELLIGENCE FOR ADVERSE DRUG REACTION PREVENTION

ADRs are a significant contributor to morbidity caused by medications. Some ADRs are known according to the known pharmacology of the medicine, while others can only be determined after its extensive use.

Clinical trials will not be able to detect all safety issues, as trials tend to have limited trial populations, shorter trial periods and controlled trial conditions. WHO therefore calls for continued monitoring of medicines for safety after they have been introduced into routine clinical practice.

AI has the potential to play a role in the prevention of ADR in a number of ways.¹²

4.1 Patient-Level Risk Prediction

Patient attributes, drug profiles, clinical history, and laboratory data can be combined into AI models to inform the prediction of an individual's risk of ADR. A risk score generated as a result of this can enable pharmacists to be identifying high risk patients, prioritizing their medication reviews, recommending further monitoring and communicating concerns with prescribers. This helps to reinforce early, individualized interventions to prevent medication-related harm.¹³

4.2 Early Detection of Safety Signals

Machine learning algorithms could process vast amounts of adverse-event data to detect trends that could signal new safety signals. It can identify changes in event frequency, severity, medication use and misuse. Some of these analyses could be used to supplement traditional pharmacovigilance approaches, allowing for quicker recognition of potential risks that will need to be evaluated in more clinical and regulatory studies.¹⁴

4.3 Pharmacovigilance Data Analysis

Pharmacovigilance involves huge amount of safety information being generated, such as the adverse-reaction reports and safety information from clinical sources. AI and sophisticated analytical tools can work efficiently with these massive volumes of information, recognize relevant patterns and help in the detection of signals. AI's integration into pharmacovigilance could enhance the efficiency and uniformity of drug safety monitoring, aid in focusing on potential medication-related risks, and elevate the effectiveness of safety surveillance.

¹²Warner, J., Prada Jardim, A., & Albera, C. (2025). Artificial intelligence: Applications in pharmacovigilance signal management. *Pharmaceutical Medicine*, 39, 183–198. <https://doi.org/10.1007/s40290-025-00561-2>

¹³Cheng, Z., Wang, Z., Tang, X., Hu, X., Yang, F., & Yan, X. (2025). A multi-view feature-based interpretable deep learning framework for drug-drug interaction prediction. *Interdisciplinary Sciences: Computational Life Sciences*, 17(2), 437–448. <https://doi.org/10.1007/s12539-025-00687-6>

¹⁴Jeong, Y. U., Choi, J., Park, N., Ryu, J. Y., & Kim, Y. R. (2025). Predicting drug-drug interactions: A deep learning approach with GCN-based collaborative filtering. *Artificial Intelligence in Medicine*, 167, 103185. <https://doi.org/10.1016/j.artmed.2025.103185>



4.4 Identifying Medication Errors

Using AI to analyse prescribing, dispensing and medication administration records, patterns could be identified that relate to medication errors. They can be used for duplicate therapy detection, contraindication checking, inappropriate dose checking, abnormal prescribing pattern, omission detection and medication reconciliation. These capabilities can contribute to the identification of patients who should be seen by a pharmacist for review and to prompt timely interventions to minimize preventable medication related harm.¹⁵

V. ROLE OF THE CLINICAL PHARMACIST IN AN AI-ENABLED SYSTEM

The clinical pharmacist must use AI to assist rather than supplant their role in medication safety practice. Pharmacists are an important part of verifying AI-generated alerts, reviewing patient-specific factors, confirming medication appropriateness, and checking for false positive or clinically irrelevant recommendations. They also report suspected ADRs, monitor the outcomes of treatment, and report to other health care professionals. A human-in-the-loop (HILO) process is required: AI Prediction, Pharmacist Interpretation, Clinical Decision and Patient Monitoring. This model integrates the strength of AI's data analysis with the clinical knowledge and expertise of pharmacists, minimizing the risk of incorrect predictions, such as false-positive or false-negative results.

VI. ADVANTAGES OF PREDICTIVE ANALYTICS FOR MEDICATION SAFETY

6.1 Early Intervention

One of the biggest benefits of predictive analytics is that it can detect patients or drug regimens that are at greater risk of poor health outcomes prior to the event happening. Early risk identification allows the pharmacist and/or healthcare professional to begin a medication review, enhanced monitoring, dose adjustment, or other prevention activities, which may limit medication harm and improve patient safety.

6.2 Processing Large Datasets

AI can analyze complex and extensive healthcare data much faster than manual methods. AI can also leverage electronic health records, medication histories, lab results, clinical notes, and pharmacovigilance reports to uncover trends and connections that might be challenging to note manually, aiding in more efficient medication-safety assessment.

6.3 Personalized Medication Management

Individual patient information, clinical factors, medication histories and lab results can be included in predictive models to facilitate personalized medication management. AI can help pharmacists and clinicians make informed decisions about the specific treatment plans for each patient, considering their unique needs and risk factors, and help optimize the monitoring of patients' response to treatment.

6.4 Improved Pharmacovigilance

AI can enhance pharmacovigilance by efficiently sifting through vast amounts of adverse event data and identifying potential safety signals for investigation. Automated pattern recognition can help identify risks emerging from medications in a timely fashion. This can enhance the effectiveness of safety surveillance and add to the knowledge and skills of pharmacovigilance personnel.

6.5 Reduction in Administrative Burden

By automating tasks like data extraction, categorization, and classification of medication-related information from clinical records, AI can ease pharmacists' administrative burden. Automated processing can help with documentation and screening, and help to monitor safety, which can free up more time for the pharmacist to spend on direct patient care, medication review, counselling, clinical decision making and other patient-centred tasks.

¹⁵OnSIDES: Extracting adverse drug events from drug labels using natural language processing models. (2025). *Journal of Biomedical Informatics*.



VII. DISCUSSION

AI is shaping a new era in clinical pharmacy, moving beyond reactive care to proactive and predictive medication safety and utilization. While traditional pharmacovigilance is still vital, AI can complement it in identifying medication signals on a faster and broader scale.

The clinical Pharmacist plays a very important role in this transition. Pharmacists hold unique expertise in pharmacotherapy, medication interactions, dosage optimization, ADRs and medication use processes. This means that Artificial Intelligence can become an analytical tool to help the pharmacist to determine the high-risk scenarios.

But, predicting the accuracy does not equal clinical effectiveness. To demonstrate that implementation of an AI system results in meaningful improvements in patient safety. Reduction of preventable ADRs, medication errors, inappropriate prescribing, hospitalisation and healthcare costs are important outcomes to include.

It is also important to consider regulatory and ethical considerations. WHO has pointed out that the governance of AI for healthcare needs to be in place, and the FDA has been working on strategies to evaluate the credibility and quality of AI applications within a drug context.

Therefore, the potential future of AI in clinical pharmacy should rely on algorithms that have been validated, robust data, clear decision making, human oversight, ongoing monitoring, and accountability.

VIII. CONCLUSION

AI and predictive analytics hold significant promise for advancing clinical pharmacy practice and medication safety. AI systems can leverage electronic health records (EHRs), medication histories, laboratory results, clinical documentation, and pharmacovigilance data to help identify patients who are at risk for adverse drug reactions, medication errors, drug–drug interactions, and other medication-related issues.

The true power of artificial intelligence lies not just in automating current processes, but in identifying risks associated with medications earlier. This may enable pharmacists to be able to intervene before preventable harm is suffered. AI can also enhance pharmacovigilance by speeding up the detection and prioritization of safety signals from the growing and complex volume of data.

However, AI cannot be a standalone solution for clinical pharmacists. To ensure broad clinical deployment, potential issues of data quality, bias, explainability, privacy, interoperability, false predictions, validation, and regulatory oversight need to be resolved.

The new model should thus be human-centered and pharmacist-led, with AI serving as an intelligent analysis and decision-making tool. Future studies should focus on prospective multicentre validation, clinically relevant outcomes, explainable AI, cost-effectiveness, interoperability and equitable implementation. AI-powered predictive analytics could be a crucial part of contemporary medication-safety and pharmacovigilance practices, provided the technology is managed properly and supervised by people. AI-powered predictive analytics technology, when managed appropriately and supervised by humans, can play a significant role in contemporary medication-safety and pharmacovigilance systems.

REFERENCES

1. Algarvio, S., et al. (2025). Artificial intelligence in pharmacovigilance: A narrative review and practical experience with an expert-defined Bayesian network tool. *International Journal of Clinical Pharmacy*. <https://doi.org/10.1007/s11096-025-01975-3>
2. Alqahtani, S. S., Menachery, S. J., Alshahrani, A., Albalkhi, B., et al. (2025). Artificial intelligence in clinical pharmacy—A systematic review of current scenario and future perspectives. *Digital Health*, 11, 20552076251388145. <https://doi.org/10.1177/20552076251388145>
3. Cheng, Z., Wang, Z., Tang, X., Hu, X., Yang, F., & Yan, X. (2025). A multi-view feature-based interpretable deep learning framework for drug-drug interaction prediction. *Interdisciplinary Sciences: Computational Life Sciences*, 17(2), 437–448. <https://doi.org/10.1007/s12539-025-00687-6>



4. Chalabianloo, N., Ahmadi, F., Omrani, M. A., et al. (2025). Machine learning methods for predicting adverse drug events: A systematic review. *British Journal of Clinical Pharmacology*, 92(2), 422–444. <https://doi.org/10.1002/bcp.70377>
5. Dsouza, V. S., Leyens, L., Kurian, J. R., Brand, A., & Brand, H. (2025). Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients. *Research in Social and Administrative Pharmacy*, 21(6), 453–462. <https://doi.org/10.1016/j.sapharm.2025.02.008>
6. Gheorghita, F.-I., Bocanet, V.-I., & Iantovics, L. B. (2025). Machine learning-based drug-drug interaction prediction: A critical review of models, limitations, and data challenges. *Frontiers in Pharmacology*. <https://doi.org/10.3389/fphar.2025.1632775>
7. Hatzimanolis, J., Riley, B., El-Den, S., Aslani, P., Zhou, J., & Chaar, B. B. (2025). Applications of artificial intelligence in current pharmacy practice: A scoping review. *Research in Social and Administrative Pharmacy*, 21(3), 134–141. <https://doi.org/10.1016/j.sapharm.2024.12.007>
8. Jeong, Y. U., Choi, J., Park, N., Ryu, J. Y., & Kim, Y. R. (2025). Predicting drug-drug interactions: A deep learning approach with GCN-based collaborative filtering. *Artificial Intelligence in Medicine*, 167, 103185. <https://doi.org/10.1016/j.artmed.2025.103185>
9. Li, Y., Tao, W., Li, Z., Sun, Z., Li, F., Fenton, S., Xu, H., & Tao, C. (2024). Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. *Journal of Biomedical Informatics*, 152, 104621. <https://doi.org/10.1016/j.jbi.2024.104621>
10. Liao, Q., Zhang, Y., Chu, Y., Ding, Y., Liu, Z., Zhao, X., Wang, Y., Wan, J., Ding, Y., Tiwari, P., Zou, Q., & Han, K. (2025). Application of artificial intelligence in drug-target interactions prediction: A review. *npj Biomedical Innovations*, 2(1), 1. <https://doi.org/10.1038/s44385-024-00003-9>
11. Senthil Kumar, R. K., & Velusamy, S. (2025). Harnessing artificial intelligence for enhanced pharmacovigilance: A comprehensive review. *Indian Journal of Pharmacy Practice*, 18(2), 171–179. <https://doi.org/10.5530/ijopp.20250145>
12. Warner, J., Prada Jardim, A., & Albera, C. (2025). Artificial intelligence: Applications in pharmacovigilance signal management. *Pharmaceutical Medicine*, 39, 183–198. <https://doi.org/10.1007/s40290-025-00561-2>
13. Cheng, Z., Wang, Z., Tang, X., Hu, X., Yang, F., & Yan, X. (2025). A multi-view feature-based interpretable deep learning framework for drug-drug interaction prediction. *Interdisciplinary Sciences: Computational Life Sciences*, 17(2), 437–448. <https://doi.org/10.1007/s12539-025-00687-6>
14. Jeong, Y. U., Choi, J., Park, N., Ryu, J. Y., & Kim, Y. R. (2025). Predicting drug-drug interactions: A deep learning approach with GCN-based collaborative filtering. *Artificial Intelligence in Medicine*, 167, 103185. <https://doi.org/10.1016/j.artmed.2025.103185>
15. OnSIDES: Extracting adverse drug events from drug labels using natural language processing models. (2025). *Journal of Biomedical Informatics*.

